Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,139.75
    +60.89 (+0.75%)
     
  • Bitcoin USD

    63,516.75
    -83.64 (-0.13%)
     
  • CMC Crypto 200

    1,325.91
    -70.63 (-5.06%)
     
  • S&P 500

    5,098.48
    +50.06 (+0.99%)
     
  • Dow

    38,174.61
    +88.81 (+0.23%)
     
  • Nasdaq

    15,924.28
    +312.52 (+2.00%)
     
  • Gold

    2,345.00
    +2.50 (+0.11%)
     
  • Crude Oil

    83.76
    +0.19 (+0.23%)
     
  • 10-Yr Bond

    4.6650
    -0.0410 (-0.87%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

This Is My Highest-Conviction Stock to Own in 2023 and Beyond

This Is My Highest-Conviction Stock to Own in 2023 and Beyond

While one could say the same about many biotech companies, Vertex has an advantage very few of its peers do: For CF patients, it's the only game in town. Vertex markets the only medicines that target the underlying causes of CF. In 2022, the company's revenue of $8.93 billion jumped by 18% year over year.